Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech A/S Adr (EVAX)
:EVAX
EVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.70 - $22.05
Previous CloseN/A
Volume99.85K
Average Volume (3M)222.09K
Market Cap
$2.17M
Enterprise ValueN/A
Total Cash (Recent Filing)$5.58M
Total Debt (Recent Filing)$10.87M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 08, 2025EPS Estimate
-1.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.54
Shares Outstanding1,173,211
10 Day Avg. Volume60,960
30 Day Avg. Volume222,092
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)159.67
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.33Price Target Upside509.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Evaxion Biotech News
PremiumCompany Announcements
Evaxion Biotech to Present at Key Conferences in 2025
PremiumCompany Announcements
Evaxion Biotech Extends Phase 2 Trial for Cancer Vaccine EVX-01PremiumCompany Announcements
Evaxion Biotech Secures Nasdaq Compliance, Strengthens Financial Position
PremiumCompany Announcements
Evaxion Biotech Expands Capital Through ADS Offering
---
Bulls Say, Bears Say
Bulls Say
AI TechnologyEvaxion is one of the pioneers and a front-runner in artificial intelligence (AI)-powered vaccine development.
Financial PerformanceEvaxion reported total revenues of $3.0M, compared to the consensus estimate of $0.1M, and a net loss of $0.04 per diluted share, compared to the consensus estimated net loss of $0.21 per share.
PartnershipsMerck led a private equity investment in Evaxion in 2023, becoming the company’s single largest shareholder, and participated a second time in a public equity offering in February 2024.
Bears Say
CompetitionThe competitive landscape favors EVX-B2 as there are no approved vaccines and development of the only clinical-stage candidate GSK4348413 was recently terminated.
RisksRisks to the Buy rating include partnership, technology, clinical, regulatory, commercial, legal and intellectual property, competition, and dilution.
---
Ownership Overview
―
Insiders
0.29% Mutual Funds
46.12% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $1.70 and its highest was $22.05 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $2.17M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is May 08, 2025 which is in 47 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Currently, no data Available
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -1.96.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 1,173,211 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
---
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech AS is an artificial intelligence immunology platform company. It uses proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market.
---
EVAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including a transformative agreement with MSD and solid pipeline progress, but also noted challenges with NASDAQ compliance and business development income targets.Read More>---
EVAX Stock 12 Month Forecast
Average Price Target
$11.33
▲(509.14% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
ImmunityBio
―
Allogene Therapeutics
―
Cullinan Management
―
Best Analysts Covering EVAX
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-69.00%
reiterated a buy rating 25 days ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -69.00% per trade.
---